NASDAQ •
Healthcare •
Biotechnology •
Quote as of 06/05/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization176.91 mln
Float8.91 mln
Earnings Date08/19/2026
Piotroski F-Score
3
/ 9
Below average
Beneish M-Score
-3.7
Highly reliable
1-Year Forecast
30.17
Transformational upside
Relative Strength
9
/ 100
Severely lagging
Debt / Equity
0.20
Very low leverage
ROE
-69.95
Deeply negative
Business Description
Founded in 2000 and based in Yavne, Israel, MediWound develops and sells biological treatments that help heal damaged tissue without surgery, operating across the United States, Europe, and other markets. Its main product, NexoBrid, is used in burn centers to remove dead tissue from serious burn wounds. The company is also working on EscharEx, an enzyme-based therapy for chronic and difficult-to-heal wounds, as well as a topical treatment for a common form of skin cancer.
